Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gil Leibowitz

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Diabetologia|February 3, 2016
Autophagy is a major regulator of beta cell insulin homeostasisYael Riahi, Jakob D Wikstrom, Etty Bachar-Wikstrom, et al.
American Journal of Physiology. Endocrinology and Metabolism|June 20, 2022
Novel roles of mTORC2 in regulation of insulin secretion by actin filament remodelingManuel Blandino-Rosano, Joshua O Scheys, Joao Pedro Werneck-de-Castro, et al.
Elife|November 10, 2018
Inhibition of mTORC1 by ER stress impairs neonatal β-cell expansion and predisposes to diabetes in the <i>Akita</i> mouseYael Riahi, Tal Israeli, Roni Yeroslaviz, et al.
Npj Metabolic Health and Disease|June 17, 2026
CD59 drives diet-induced obesity and glucose intolerance, insulin resistance, and metabolic dysfunction-associated steatotic liver diseaseMarian Zeibak, Netanel Karbian, Yael Riahi, et al.
Molecular Metabolism|June 23, 2025
Metabolic consequences of altered kidney glucose reabsorption under normoglycemic conditionsMajdoleen Ahmad, Anna Permyakova, Saja Baraghithy, et al.
The Journal of Clinical Investigation|January 2, 2026
JNK3 regulates β cell responses to incretins in human islets and mouse modelsRuy A Louzada, Marel Gonzalez Medina, Valentina Pita-Grisanti, et al.
Diabetologia|July 22, 2023
Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon productionYael Riahi, Aviram Kogot-Levin, Liat Kadosh, et al.
Diabetes Care|May 26, 2016
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 TrialAvivit Cahn, Itamar Raz, Ofri Mosenzon, et al.
Diabetes Care|November 1, 2016
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 TrialOfri Mosenzon, Gil Leibowitz, Deepak L Bhatt, et al.
Journal of the American Society of Nephrology : JASN|October 15, 2017
Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic NephropathyLiad Hinden, Shiran Udi, Adi Drori, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Diabetologia|February 3, 2016
Autophagy is a major regulator of beta cell insulin homeostasisYael Riahi, Jakob D Wikstrom, Etty Bachar-Wikstrom, et al.
American Journal of Physiology. Endocrinology and Metabolism|June 20, 2022
Novel roles of mTORC2 in regulation of insulin secretion by actin filament remodelingManuel Blandino-Rosano, Joshua O Scheys, Joao Pedro Werneck-de-Castro, et al.
Elife|November 10, 2018
Inhibition of mTORC1 by ER stress impairs neonatal β-cell expansion and predisposes to diabetes in the <i>Akita</i> mouseYael Riahi, Tal Israeli, Roni Yeroslaviz, et al.
Npj Metabolic Health and Disease|June 17, 2026
CD59 drives diet-induced obesity and glucose intolerance, insulin resistance, and metabolic dysfunction-associated steatotic liver diseaseMarian Zeibak, Netanel Karbian, Yael Riahi, et al.
Molecular Metabolism|June 23, 2025
Metabolic consequences of altered kidney glucose reabsorption under normoglycemic conditionsMajdoleen Ahmad, Anna Permyakova, Saja Baraghithy, et al.
The Journal of Clinical Investigation|January 2, 2026
JNK3 regulates β cell responses to incretins in human islets and mouse modelsRuy A Louzada, Marel Gonzalez Medina, Valentina Pita-Grisanti, et al.
Diabetologia|July 22, 2023
Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon productionYael Riahi, Aviram Kogot-Levin, Liat Kadosh, et al.
Diabetes Care|May 26, 2016
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 TrialAvivit Cahn, Itamar Raz, Ofri Mosenzon, et al.
Diabetes Care|November 1, 2016
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 TrialOfri Mosenzon, Gil Leibowitz, Deepak L Bhatt, et al.
Journal of the American Society of Nephrology : JASN|October 15, 2017
Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic NephropathyLiad Hinden, Shiran Udi, Adi Drori, et al.
Pageof 7